A webinar for scientists interested in the use of implantable pumps as an alternative to serial injections when administering compounds to laboratory animals.

The administration of compounds and dosing methodologies are important considerations when planning experiments using laboratory animals. Injections are often used for animal dosing, but repeated injections over prolonged periods may be inadequate for some compounds (i.e. those with short half-lives) and can lead to great variations in serum concentrations. They are also stressful to the animal and inconvenient for the researcher.

Implantable infusion pumps offer a reliable and convenient alternative to injections and other repetitive dosing methods. They allow greater control and accuracy in drug delivery, thus reducing dosing errors, ensuring stable dose levels and minimizing adverse effects. ALZET® Osmotic Pumps have been used in preclinical research for nearly four decades to successfully deliver a wide range of experimental agents. iPRECIO® programmable pumps have been developed more recently to facilitate highly demanding dosing requirements.

In this exclusive webinar sponsored by DURECT Corporation, Mr. José Gadea describes the features, benefits and applications of implantable pumps. Discussion focuses on clarifying the most common misconceptions circulating within the research community about implantable infusion pumps. This information is intended to help researchers make more informed decisions when choosing the most appropriate dosing method for their study.

Resources

To download a PDF copy of the presentation, click on the “LinkedIn SlideShare” icon located in the bottom-right corner of the slide-viewer. From the SlideShare landing page click the “Download” button to retrieve the file.

Presenters

Sr. Product Marketing Manager
ALZET

José Gadea has over 15 years of technical and marketing experience working with ALZET® Osmotic Pumps. José currently holds the position of Senior Product Marketing Manager for ALZET pumps and ancillary products at DURECT Corporation. Prior to DURECT, José worked as a therapeutic sales specialist for ALZA Pharmaceuticals. He also has over five years of combined academic and biotechnology research experience in the fields of cancer immunology, cell and gene therapy, infectious diseases, and drug delivery. José earned his Bachelor of Science degree with concentration in Medical Microbiology & Immunology at San Jose State University, California.

Production Partner

DURECT Corporation

DURECT is committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.

Related Content